H.C. Wainwright Reiterates Buy on Omeros After AstraZeneca’s Ultomiris Phase 3 Miss
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.
/ 492 items
#XY Event-Driven Stocks↓
Positive ZEPHYR Trial Results Fail to Impress Investors as MapLight Stock Plunges
MapLight ZEPHYR trial: BID dose hits primary endpoint & cognitive goals, but QD misses; shares plunge over 60% on mixed schizophrenia data.
Gossamer Bio Stock Surges on FDA Progress and Worldwide Rights Win for Seralutinib
A productive FDA Pre-NDA meeting paves the way for a September 2026 NDA filing for seralutinib in PAH and the return of full rights.
Argenx Expands Immunology Pipeline with $2.2B Forte Deal
Argenx acquires Forte Biosciences for $77/share, adding the first-in-class FB102 anti-CD122 antibody to expand its immunology pipeline for autoimmune diseases.
Hims & Hers Shares Plunge After FDA Panel’s First ‘No’ on a Popular Peptide
Hims & Hers shares fell after FDA advisers approved six peptides for compounding but rejected the sleep-related peptide emideltide.
FDA Approves Lytenava: First Official Eye-Only Version of Bevacizumab for Wet AMD
Purpose-built for the eye, it ends years of off-label repackaging.